Pluristem's PLX Cells Demonstrate Favorable Properties in Treatment of Tendon Injuries

Pluristem Therapeutics Inc. (NASDAQ: PSTI ) announced today the results of a pre-clinical trial using the Company's PLacental eXpanded (PLX) cells in tendon injury. Dr. Scott Rodeo and his orthopedic research team at New York's Hospital for Special Surgery (HSS) studied the effects of PLX cells on rat patellar